Decreased CD127 expression on T cells in HIV-1-infected adults receiving antiretroviral therapy with or without intermittent IL-2 therapy

Journal of Acquired Immune Deficiency Syndromes

Volumn 42, Issue 5, 2006, Pages 537-544

  Read, Sarah W ^a   Higgins, Jeanette ^b   Metcalf, Julia A ^a   Stevens, Randy A ^b   Rupert, Adam ^b   Nason, Martha C ^a   Lane, H Clifford ^a   Sereti, Irini ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b SAIC FREDERICK INC   (United States)

Author keywords

CD25; HAART; Immune activation; Interleukin 2; Interleukin 7

Indexed keywords

ANTIRETROVIRUS AGENT; INTERLEUKIN 2; INTERLEUKIN 7; INTERLEUKIN 7 RECEPTOR;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; EFFECTOR CELL; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MALE; MEMORY CELL; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; T LYMPHOCYTE SUBPOPULATION; TREATMENT OUTCOME;

ADULT; AGED; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; FLOW CYTOMETRY; HIV INFECTIONS; HUMANS; INTERLEUKIN-2; INTERLEUKIN-7; LYMPHOCYTE SUBSETS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RECEPTORS, INTERLEUKIN-2; RECEPTORS, INTERLEUKIN-7; STATISTICS; T-LYMPHOCYTES;

EID: 33746690674     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000223027.47456.d0     Document Type: Article

References (34)

1. Fry TJ, Mackall CL. Interleukin-7: from bench to clinic. Blood. 2002;99:3892-3904.
2. Pallard C, Stegmann AP, van Kleffens T, et al. Distinct roles of the phosphatidylinositol 3-kinase and STAT5 pathways in IL-7-mediated development of human thymocyte precursors. Immunity. 1999;10:525-535.
3. DiSanto JP, Aifantis I, Rosmaraki E, et al. The common cytokine receptor gamma chain and the pre-T cell receptor provide independent but critically overlapping signals in early alpha/beta T cell development. J Exp Med. 1999;189:563-573.
4. Rathmell JC, Farkash EA, Gao W, et al. IL-7 enhances the survival and maintains the size of naïve T cells. J Immunol. 2001;167:6869-6876.
5. Tan JT, Dudl E, LeRoy E, et al. IL-7 is critical for homeostatic proliferation and survival of naïve T cells. Proc Natl Acad Sci U S A. 2001;98:8732-8737.
6. Kaech SM, Tan JT, Wherry EJ, et al. Selective expression of the interleukin-7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells. Nat Immunol. 2003;4:1191-1198.
7. Kondrack RM, Harbertson J, Tan JT, et al. Interleukin 7 regulates the survival and generation of memory CD4 cells. J Exp Med. 2003;198:1797-1806.
8. Li JC, Huston G, Swain SL. IL-7 promotes the transition of CD4 effectors to persistent memory cells. J Exp Med. 2003;198:1807-1815.
9. Fry TJ, Connick E, Falloon J, et al. A potential role for interleukin-7 in T-cell homeostasis. Blood. 2001;97:2983-2990.
10. Napolitano LA, Grant RM, Deeks SG, et al. Increased production of IL-7 accompanies HIV-1-mediated T-cell depletion: implication for T-cell homeostasis. Nat Med. 2001;7:73-79.
11. Mackall CL, Fry TJ, Bare C, et al. IL-7 increases both thymic-dependent and thymic-independent T-cell regeneration after bone marrow transplantation. Blood. 2001;97:1491-1497.
12. Fry TJ, Moniuszko M, Creekmore S, et al. IL-7 therapy dramatically alters peripheral T-cell homeostasis in normal and SIV-infected nonhuman primates. Blood. 2003;101:2294-2299.
13. Ozaki K, Leonard WJ. Cytokine and cytokine receptor pleiotropy and redundancy. J Biol Chem. 2002;277:29355-29358.
14. Vingerhoets J, Bisalinkumi E, Penne G, et al. Altered receptor expression and decreased sensitivity of T-cells to the stimulatory cytokines IL-2, IL-7 and IL-12 in HIV infection. Immunol Lett. 1998;61:53-61.
15. + T cells is reduced in HIV infection and partially restored with effective antiretroviral therapy. J Acquir Immune Defic Syndr. 2001;28:454-457.
16. Kovacs JA, Baseler M, Dewar RJ, et al. Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. A preliminary study. N Eng J Med. 1995;332:567-575.
17. Davey RT, Chaitt DG, Albert JM, et al. A randomized trial of high- versus low-dose subcutaneous interleukin-2 outpatient therapy for early human immunodeficiency virus type 1 infection. J Infect Dis. 1999;179:849-858.
18. Davey RT, Murphy RL, Graziano FM, et al. Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy: a randomized controlled trial. JAMA. 2000;284:183-189.
19. + T-cell expansion in HIV-infected patients is associated with long-term decreases in T-cell proliferation. Blood. 2004;104:775-780.
20. Sereti I, Imamichi H, Natarajan V, et al. In vivo expansion of CD4+CD45RO-CD25+ T cells expressing foxP3 in IL-2-treated HIV-infected patients. J Clin Invest. 2005;115:1839-1847.
21. + T lymphocytes by intermittent IL-2 therapy in HIV-infected patients. J Clin Invest. 2005;115:2139-2148.
22. Marchetti G, Meroni L, Varchetta S, et al. Low-dose prolonged intermittent interleukin-2 adjuvant therapy: results of a randomized trial among human immunodeficiency virus-positive patients with advanced immune impairment. J Infect Dis. 2002;186:606-616.
23. Beq S, Fontanet A, Theze J, et al. IL-7 and Flt-3L plasma levels are increased during highly active antiretroviral therapy-associated IL-2 therapy. AIDS. 2004;18:2089-2091.
24. Marchetti G, Meroni L, Molteni C, et al. IL-7/IL-7 receptor system regulation following IL-2 immunotherapy in HIV-infected patients. Antivir Ther. 2004;9:447-452.
25. Xue HH, Kovanen PE, Pise-Masison CA, et al. IL-2 negatively regulates IL-7 receptor alpha chain expression in activated T lymphocytes. Proc Natl Acad Sci U S A. 2002;99:13759-13764.
26. Park JH, Yu Q, Erman B, et al. Suppression of IL7Ralpha transcription by IL-7 and other prosurvival cytokines: a novel mechanism for maximizing IL-7-dependent T cell survival. Immunity. 2004;21:289-302.
27. De Paoli P, Zanussi S, Simonelli C, et al. Effects of subcutaneous interleukin-2 therapy on CD4 subsets and in vitro cytokine production in HIV+ subjects. J Clin Invest. 1997;100:2737-2743.
28. + T cells. Blood. 2002;100:2159-2167.
29. Mastroianni CM, Forcina G, d'Ettorre G, et al. Circulating levels of interleukin-7 in antiretroviral-naïve and highly active antiretroviral therapy-treated HIV-infected patients. HIV Clin Trials. 2001;2:108-112.
30. Llano A, Barretina J, Gutierrez A, et al. Interleukin-7 in plasma correlates with CD4 T-cell depletion and may be associated with emergence of syncytium-inducing variants in human immunodeficiency virus type 1-positive individuals. J Virol. 2001;75:10319-10325.
31. Darcissac EC, Vidal V, De La Tribonniere X, et al. Variations in serum IL-7 and 90K/Mac-2 binding protein (Mac-2 BP) levels analysed in cohorts of HIV-1 patients and correlated with clinical changes following antiretroviral therapy. Clin Exp Immunol. 2001;126:287-294.
32. Mussini C, Pinti M, Borghi V, et al. Features of 'CD4-exploders', HIV-positive patients with an optimal immune reconstitution after potent antiretroviral therapy. AIDS. 2002;16:1609-1616.
33. + T cells in HIV-infected individuals. J Immunol. 2005;174:2900-2909.
34. Nugeyre MT, Monceaux V, Beq S, et al. IL-7 stimulates T cell renewal without increasing viral replication in simian immunodeficiency virus-infected macaques. J Immunol. 2003;171:4447-4453.